Mikaela Sjöstrand
AstraZeneca (Sweden)(SE)
Publications by Year
Research Areas
Diabetes Treatment and Management, Pancreatic function and diabetes, Cardiovascular Function and Risk Factors, Diabetes Management and Research, Heart Failure Treatment and Management
Most-Cited Works
- → Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction(2019)6,600 cited
- → Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes(2020)526 cited
- → A Trial to Evaluate the Effect of the Sodium–Glucose Co-Transporter 2 Inhibitor Dapagliflozin on Morbidity and Mortality in Patients with Heart Failure and Reduced Left Ventricular Ejection Fraction (DAPA-HF)(2019)437 cited
- → Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction(2019)341 cited
- → Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction(2020)295 cited
- → Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF(2021)249 cited
- → The Dapagliflozin And Prevention of Adverse-Outcomes in Heart Failure (DAPA-HF) Trial: Baseline Characteristics(2019)217 cited
- → Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age(2019)202 cited
- → Effects of dapagliflozin in DAPA-HF according to background heart failure therapy(2020)190 cited
- → Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction(2021)182 cited